PharmaShots | Incisive News in 3 Shots

Subscribe Now

springworks therapeutics

SpringWorks Therapeutics Receives US FDA Approval for Gomekli to Treat Neurofibromatosis Type 1 Associated Symptomatic Plexiform Neurofibromas (NF1-PN)

SpringWorks Therapeutics Receives US FDA Approval for Gomekli to Treat Neurofibromatosis Type 1 Associated Symptomatic Plexiform N...

February 12, 2025

SpringWorks Therapeutics Reports the Results for Mirdametinib in P-IIb Trial to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)

SpringWorks Therapeutics Reports the Results for Mirdametinib in P-IIb Trial to Treat Neurofibromatosis Type 1-Associated Plexifor...

November 17, 2023

SpringWorks Therapeutics Reports the US FDA Acceptance of NDA and Granted Priority Review of Nirogacestat for Desmoid Tumors

SpringWorks Therapeutics Reports the US FDA Acceptance of NDA and Granted Priority Review of Nirogacestat for Desmoid Tumors

February 28, 2023

SpringWorks Therapeutics Reports First Patient Dosing in the P-II Trial of Nirogacestat for the Treatment of Ovarian Granulosa Cell Tumors

SpringWorks Therapeutics Reports First Patient Dosing in the P-II Trial of Nirogacestat for the Treatment of Ovarian Granulosa Cel...

September 30, 2022

SpringWorks Therapeutics Presents P-III (DeFi) Trial Results of Nirogacestat for the Treatment of Progressing Desmoid Tumors at ESMO 2022

SpringWorks Therapeutics Presents P-III (DeFi) Trial Results of Nirogacestat for the Treatment of Progressing Desmoid Tumors at ES...

August 22, 2022

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

October 6, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us